Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 62
Semaglutide after GDM: the SERENA trial
A Belgian RCT tests semaglutide 1 mg in 252 women with postpartum prediabetes after gestational diabetes to see if it can prevent type 2 diabetes.
Tirzepatide: what real-world users report
A 2026 real-world survey of 151 US physicians and 199 patients found high satisfaction with once-weekly tirzepatide for obesity, plus clear limits.
Tirzepatide: real-world survey 2026
A 2026 survey of 151 physicians and 199 patients found over 90% would recommend tirzepatide, and 78.5% of physicians rated obesity outcomes a success.
BPC-157 UK import rules for personal use
UK law exempts personal imports of medicines from the manufacturer's licence rule. Selling or advertising BPC-157 in the UK is a different question entirely.
Bremelanotide stability: 8 degradants
A July 2026 analytical study characterized eight degradation products of bremelanotide acetate and predicted which chiral centers epimerize under stress.
BPC-157 UK import rules: the MHRA position
BPC-157 has no UK marketing authorisation and no approved import route for personal use. Here is what the MHRA framework and border rules mean.
What GLP-1 labels say is worth tracking
The semaglutide and tirzepatide labels name specific things to monitor on a GLP-1, and the list is not the one a weight graph suggests.
What to track on a peptide protocol
Structured logging of dose schedule, injection sites, side effects, and body metrics helps clinicians manage GLP-1 and peptide protocols effectively.
Peptides after surgery: the evidence
BPC-157, GHK-Cu and KPV get discussed as post-surgical recovery aids. No human trial has measured what any of them does to a healing surgical wound.
BPC-157, GHK-Cu and KPV after surgery
What the animal literature says about BPC-157, GHK-Cu, and KPV and post-surgical healing, and why the human evidence to guide restart timing does not yet exist.
PT-141 in women: onset and side effects
The RECONNECT Phase 3 trials enrolled 1,247 premenopausal women and documented onset timing, nausea rates, and the cardiovascular signal for bremelanotide.
Retatrutide's overstimulated side effects
Forum users describe a wired, foggy feeling on retatrutide. Here is what the phase 2 trials recorded, and the large gap between that and anecdote.